Literature DB >> 11695720

Gender difference in ifosfamide metabolism by human liver microsomes.

R Schmidt1, F Baumann, H Hanschmann, F Geissler, R Preiss.   

Abstract

Pharmacokinetic gender-dependent differences in cytochrome P450-mediated drug metabolism, especially CYP3A4, and their clinical implications are increasingly apparent. CYP3A4 seems to be the most important CYP isoform in both bioactivation and N-dechloroethylation of the alkylating prodrug ifosfamide, but informations about possible gender-related differences are lacking. Therefore we compared in 10 male and 10 female liver microsomal preparations the contents and activities of specific isoenzymes, involved in both metabolic pathways, especially CYP3A4, further CYP2A6, CYP2C9 and CYP2B6 and measured the in vitro activities of these microsomes in the ifosfamide 4-hydroxylation and N-dechloroethylation using high-sensitive HPLC/MS and -UV detection methods. Statistically significant differences between male and female livers were found in the mean CYP3A4 contents and activities. These differences had no consequences on the ifosfamide 4-hydroxylation activities of liver microsomes in vitro. In contrast, in the ifosfamide N-dechloroethylation reaction we found a statistically significant difference between the liver microsomes of male and female patients (0.13 +/- 0.05 nmol/min nmol P450 vs. 0.28 +/- 0.13 nmol/min x nmolP450, respectively). In conclusion, we firstly demonstrated such gender-related difference in the ifosfamide N-dechloroethylation, which could result in a higher risk of partly severe neurotoxic side effects in female patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11695720     DOI: 10.1007/BF03190396

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.569


  32 in total

1.  Ifosfamide cytotoxicity on human tumor and renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide.

Authors:  S K Brüggemann; J Kisro; T Wagner
Journal:  Cancer Res       Date:  1997-07-01       Impact factor: 12.701

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Ifosfamide encephalopathy: a reappraisal.

Authors:  S W Watkin; D J Husband; J A Green; H M Warenius
Journal:  Eur J Cancer Clin Oncol       Date:  1989-09

4.  Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer.

Authors:  P Roy; O Tretyakov; J Wright; D J Waxman
Journal:  Drug Metab Dispos       Date:  1999-11       Impact factor: 3.922

5.  Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes.

Authors:  C P Granvil; A Madan; M Sharkawi; A Parkinson; I W Wainer
Journal:  Drug Metab Dispos       Date:  1999-04       Impact factor: 3.922

6.  Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide.

Authors:  Z Huang; P Roy; D J Waxman
Journal:  Biochem Pharmacol       Date:  2000-04-15       Impact factor: 5.858

7.  Efficacy, toxicity, pharmacokinetics, and in vitro metabolism of the enantiomers of ifosfamide in mice.

Authors:  D Masurel; P J Houghton; C L Young; I W Wainer
Journal:  Cancer Res       Date:  1990-01-15       Impact factor: 12.701

8.  Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide.

Authors:  D Walker; J P Flinois; S C Monkman; C Beloc; A V Boddy; S Cholerton; A K Daly; M J Lind; A D Pearson; P H Beaune
Journal:  Biochem Pharmacol       Date:  1994-03-29       Impact factor: 5.858

Review 9.  Gender differences in pharmacokinetics.

Authors:  C H Gleiter; U Gundert-Remy
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

10.  Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily.

Authors:  M V Relling; T Aoyama; F J Gonzalez; U A Meyer
Journal:  J Pharmacol Exp Ther       Date:  1990-01       Impact factor: 4.030

View more
  14 in total

Review 1.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

Authors:  Ron H N van Schaik
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

2.  Bioavailability of cinnarizine in dogs: effect of SNEDDS loading level and correlation with cinnarizine solubilization during in vitro lipolysis.

Authors:  Anne T Larsen; Pernilla Åkesson; Anna Juréus; Lasse Saaby; Ragheb Abu-Rmaileh; Bertil Abrahamsson; Jesper Østergaard; Anette Müllertz
Journal:  Pharm Res       Date:  2013-08-15       Impact factor: 4.200

Review 3.  Gender aspects in cardiovascular pharmacology.

Authors:  Sabine Oertelt-Prigione; Vera Regitz-Zagrosek
Journal:  J Cardiovasc Transl Res       Date:  2009-06-12       Impact factor: 4.132

4.  Intra- and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese.

Authors:  Su Guan; Min Huang; Xin Li; Xiao Chen; Eli Chan; Shu-Feng Zhou
Journal:  Pharm Res       Date:  2006-08-09       Impact factor: 4.200

Review 5.  Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.

Authors:  Enoch Cobbina; Fatemeh Akhlaghi
Journal:  Drug Metab Rev       Date:  2017-03-17       Impact factor: 4.518

Review 6.  Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature.

Authors:  Karen I Sweiss; Rakesh Beri; Stacy S Shord
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 7.  Sex differences in the expression of hepatic drug metabolizing enzymes.

Authors:  David J Waxman; Minita G Holloway
Journal:  Mol Pharmacol       Date:  2009-05-29       Impact factor: 4.436

8.  Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.

Authors:  Trine Naalsund Andreassen; Pål Klepstad; Andrew Davies; Kristin Bjordal; Staffan Lundström; Stein Kaasa; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2010-12-08       Impact factor: 2.953

9.  CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes.

Authors:  R Schmidt; F Baumann; H Knüpfer; M Brauckhoff; L-C Horn; M Schönfelder; U Köhler; R Preiss
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

Review 10.  Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies.

Authors:  Smarakan Sneha; Simon C Baker; Andrew Green; Sarah Storr; Radhika Aiyappa; Stewart Martin; Klaus Pors
Journal:  Biomedicines       Date:  2021-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.